Journal
STEM CELL REPORTS
Volume 10, Issue 3, Pages 1059-1074Publisher
CELL PRESS
DOI: 10.1016/j.stemcr.2018.01.032
Keywords
-
Categories
Funding
- RIKEN
- AMED [17bm0204002h0005]
- Sumitomo Dainippon Pharma
- Grants-in-Aid for Scientific Research [15K10913, 15KT0086, 17H04351, 17K16994] Funding Source: KAKEN
Ask authors/readers for more resources
Increasing demand for clinical retinal degeneration therapies featuring human ESC/iPSC-derived retinal tissue and cells warrants proof-of-concept studies. Here, we established two mouse models of end-stage retinal degeneration with immunodeficiency, NOG-rd1-2J and NOG-rd10, and characterized disease progress and immunodeficient status. We also transplanted human ESC-derived retinal sheets into NOG-rd1-2J and confirmed their long-term survival and maturation of the structured graft photoreceptor layer, without rejection or tumorigenesis. We recorded light responses from the host ganglion cells using a multi-electrode array system; this result was consistent with whole-mount immunostaining suggestive of host-graft synapse formation at the responding sites. This study demonstrates an application of our mouse models and provides a proof of concept for the clinical use of human ESC-derived retinal sheets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available